Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Marion Eveillard, PharmD, PhD, Victor Floc'h, Nelly Robillard, PhD, Camille Debord, Soraya Wuilleme, PharmD, PhD, Richard Garand, Fanny Rialland, MD, Caroline Thomas, Pierre Peterlin, MD, Thierry Guillaume, MD PhD, Philippe Moreau, Patrice Chevallier, MD PhD, Marie C Bene, PharmSciD, PhD

Blood (2016) 128 (22): 5268.

https://doi.org/10.1182/blood.V128.22.5268.5268

Published: 2016

Journal Articles

Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

Marion Eveillard, Nelly Robillard, Richard Garand, MD, Fanny Rialland, MD, Nicolas Blin, MD, Marion Strullu, Caroline Thomas, MD, Chantal Fossat, Isabelle Arnoux, Marie-Christine Bene, PharmSciD, PhD, Marie Loosveld

Blood (2014) 124 (21): 5358.

https://doi.org/10.1182/blood.V124.21.5358.5358

Published: 2014

Journal Articles

Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia

Marion Eveillard, Richard Garand, MD, Nelly Robillard, Soraya Wuilleme, MD, PhD, Caroline Thomas, M.D., Marion Strullu, Fanny Rialland, M.D., Jacques Delaunay, MD, Patrice Chevallier, MD, PhD, Philippe Moreau, MD, Nicolas Blin, Marie-Christine Bene, PharmSciD, PhD

Blood (2013) 122 (21): 4954.

https://doi.org/10.1182/blood.V122.21.4954.4954

Published: 2013

Journal Articles

Prognostic Impact of Bone Marrow B Lymphocyte Precursors (hematogones) Detection in 95 Acute Lymphoblastic Leukemia Cases

Sylvain P Chantepie, MD, Audrey Emmanuelle Dugué, MD, Patrice Chevallier, MD, PhD, Aline Schmidt-Tanguy, MD, Véronique Salaün, PhD, Richard Garand, MD, Marion Eveillard, MD, Oumedaly Reman, MD

Blood (2012) 120 (21): 4791.

https://doi.org/10.1182/blood.V120.21.4791.4791

Published: 2012

Journal Articles

Evaluation of the Intra-LABORATORY Reproducibility of Percentage of Blast Counting In MYELODYSPLASIA

Soraya Wuilleme, MD, PhD, Marion Eveillard, Sophie Barillet, Françoise Accard, Hervé Avet-Loiseau, MD, PhD, Jacques Delaunay, MD, Richard Garand

Blood (2011) 118 (21): 4901.

https://doi.org/10.1182/blood.V118.21.4901.4901

Published: 2011

Journal Articles

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

Blood (2010) 116 (21): 4113.

https://doi.org/10.1182/blood.V116.21.4113.4113

Published: 2010

Journal Articles

Morphology, Cytogenetics and Survival In myelodysplasia with Del(20q) or Ider(20q): a Multicentric Study

François Mullier, Sylvie Daliphard, Richard Garand, Mélanie Dekeyser, Yvan Cornet, Isabelle Luquet, MD, PhD, Pascaline Talmant, Steven Richebourg, Mauricette Jamar, Jean-Michel Dogné, Christian Chatelain, Lucienne Michaux, Bernard Chatelain

Blood (2010) 116 (21): 2942.

https://doi.org/10.1182/blood.V116.21.2942.2942

Published: 2010

Journal Articles

Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM).

Xavier Leleu, Jean E. Goasguen, MD, PhD, Claire Mathiot, MD, Richard Garand, PhD, Murielle Roussel, MD, Michel Attal, MD, Philippe Moreau, MD, Jean-Luc Harousseau, MD, Thierry Facon, MD, Hervé Avet-Loiseau, MD, PhD, Marc Zandecki, PhD

Blood (2009) 114 (22): 1822.

https://doi.org/10.1182/blood.V114.22.1822.1822

Published: 2009

Journal Articles

IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements.

Laurence Lode, Surinder S. Sahota, PhD, Soraya Wuilleme, Steven Richebourg, Marion Eveillard, Regis Bataille, Herve Avet Loiseau, MD, PhD, Richard Garand, MD

Blood (2008) 112 (11): 1778.

https://doi.org/10.1182/blood.V112.11.1778.1778

Published: 2008

Journal Articles

Prognostic Value of Cytogenetics in Patients with Acute Myeloid Leukemia Aged More Than 60 Years at Diagnosis: Identification of Subgroups Taking Benefit from Intensive Chemotherapy. Results from a Large Single Center Retrospective Study.

Nicolas Blin, MD, Pascaline Talmant, MD, Richard Garand, MD, Francoise Accard, MD, Philippe Moreau, MD, Jean-Luc Harousseau, MD, Herve Avet-Loiseau, MD, PhD

Blood (2007) 110 (11): 3503.

https://doi.org/10.1182/blood.V110.11.3503.3503

Published: 2007

Journal Articles

Leukemic blasts in transformed JAK2-V617F –positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Alexandre Theocharides, Marjorie Boissinot, François Girodon, Richard Garand, Soon-Siong Teo, Eric Lippert, Pascaline Talmant, Andre Tichelli, Sylvie Hermouet, Radek C. Skoda

Blood (2007) 110 (1): 375–379.

https://doi.org/10.1182/blood-2006-12-062125

Published: 2007

Includes: Supplemental data

Journal Articles

MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.

Patrice Chevallier, MD, Noel Milpied, MD, Mathilde Hunault-Berger, MD, Richard Garand, MD, Philippe Moreau, MD, Jacques Delaunay, MD, Thierry Guillaume, MD, Jean-Luc Harousseau, MD

Blood (2006) 108 (11): 1957.

https://doi.org/10.1182/blood.V108.11.1957.1957

Published: 2006

Journal Articles

Acute Lymphoblastic Leukemia Occurring in Patient with Acute Myeloid Leukaemia: An Unrelated Leukemia Rather Than a Therapy-Related Malignancy. About 2 Cases.

Chadi El-Nawakil, MD, Richard Garand, MD, Stephane Vigouroux, MD, Jean-Luc Harousseau, MD, Patrice Chevallier, MD

Blood (2006) 108 (11): 4470.

https://doi.org/10.1182/blood.V108.11.4470.4470

Published: 2006

Journal Articles

Myeloid Blasts in Transformed JAK2-V617F Positive Myeloproliferative Disorders Are Frequently Negative for the JAK2-V617F Mutation.

Alexandre Theocharides, Marjorie Boissinot, Richard Garand, François Girodon, Soon-Siong Teo, Eric Lippert, Andre Tichelli, Sylvie Hermouet, Radek C. Skoda

Blood (2006) 108 (11): 375.

https://doi.org/10.1182/blood.V108.11.375.375

Published: 2006

Journal Articles

High Grade Non-Hodgkin’s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.

Cyrille Touzeau, Pascaline Talmant, Anne Moreau, Richard Garand, Herve Avet-Loiseau, Nadine Juge-Morineau, Thomas Gastinne, Philippe Moreau, Jean-Luc Harousseau, Steven Le Gouill

Blood (2006) 108 (11): 2045.

https://doi.org/10.1182/blood.V108.11.2045.2045

Published: 2006

Journal Articles

The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)

Marjorie Boissinot, Richard Garand, Mohamed Hamidou, Sylvie Hermouet

Blood (2006) 108 (5): 1781–1782.

https://doi.org/10.1182/blood-2006-03-008227

Published: 2006

Journal Articles

IgM-Expressing Waldenstrom’s Macroglobulinemia Tumor Cells Reveal a Potential for Isotype Switch.

Surinder S. Sahota, PhD, Gavin Babbage, B.Sc, Mark Townsend, B.Sc, Ian C. Mockridge, B.Sc, M.Phil, Niklas Zojer, MD, Richard Garand, MD, John Shaughnessy, Jr., Ph.D, Freda K. Stevenson, D.Phil

Blood (2005) 106 (11): 994.

https://doi.org/10.1182/blood.V106.11.994.994

Published: 2005

Journal Articles

Mylotarg 9 mg/m ² Combined with Intermediate Dose Aracytin and Mitoxantrone (MIDAM) in Relapsed/Refractory CD33+ Acute Myeloid Leukemia: A Single Center Phase II Experience.

Patrice Chevallier, Virginie Rolland, Richard Garand, Herve Avet-Loiseau, Beatrice Mahe, Philippe Moreau, Noel Milpied, Jean-Luc Harousseau

Blood (2004) 104 (11): 1811.

https://doi.org/10.1182/blood.V104.11.1811.1811

Published: 2004

Journal Articles

Mantle cell lymphoma with t(11;14) and unmutated or mutated V H genes expresses AID and undergoes isotype switch events

Gavin Babbage, Richard Garand, Nelly Robillard, Niklas Zojer, Freda K. Stevenson, Surinder S. Sahota

Blood (2004) 103 (7): 2795–2798.

https://doi.org/10.1182/blood-2003-05-1632

Published: 2004

Journal Articles

CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage

Vahid Asnafi, Isabelle Radford-Weiss, Nicole Dastugue, Chantal Bayle, Daniel Leboeuf, Christiane Charrin, Richard Garand, Marina Lafage-Pochitaloff, Eric Delabesse, Agnès Buzyn, Xavier Troussard, Elizabeth Macintyre

Blood (2003) 102 (3): 1000–1006.

https://doi.org/10.1182/blood-2002-09-2913

Published: 2003

NARROW

CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy

Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders

Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia

Prognostic Impact of Bone Marrow B Lymphocyte Precursors (hematogones) Detection in 95 Acute Lymphoblastic Leukemia Cases

Evaluation of the Intra-LABORATORY Reproducibility of Percentage of Blast Counting In MYELODYSPLASIA

Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients

Morphology, Cytogenetics and Survival In myelodysplasia with Del(20q) or Ider(20q): a Multicentric Study

Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM).

IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements.

Prognostic Value of Cytogenetics in Patients with Acute Myeloid Leukemia Aged More Than 60 Years at Diagnosis: Identification of Subgroups Taking Benefit from Intensive Chemotherapy. Results from a Large Single Center Retrospective Study.

Leukemic blasts in transformed JAK2-V617F –positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.

Acute Lymphoblastic Leukemia Occurring in Patient with Acute Myeloid Leukaemia: An Unrelated Leukemia Rather Than a Therapy-Related Malignancy. About 2 Cases.

Myeloid Blasts in Transformed JAK2-V617F Positive Myeloproliferative Disorders Are Frequently Negative for the JAK2-V617F Mutation.

High Grade Non-Hodgkin’s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.

The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)

IgM-Expressing Waldenstrom’s Macroglobulinemia Tumor Cells Reveal a Potential for Isotype Switch.

Mylotarg 9 mg/m ² Combined with Intermediate Dose Aracytin and Mitoxantrone (MIDAM) in Relapsed/Refractory CD33+ Acute Myeloid Leukemia: A Single Center Phase II Experience.

Mantle cell lymphoma with t(11;14) and unmutated or mutated V H genes expresses AID and undergoes isotype switch events

CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRγδ lineage

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only